Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9974037 | 0.82 | BRD4 (0.73) | BRD4 | |
| SCHEMBL9974005 | 0.81 | BRD4 (0.48) | BRD4 | |
| SCHEMBL9281955 | 0.80 | BRD4 (0.59) | BRD4 | |
| SCHEMBL9278515 | 0.77 | BRD4 (0.47) | BRD4 | |
| SCHEMBL9974038 | 0.70 | BRD4 (0.74) | BRD4 | |
| SCHEMBL9974035 | 0.69 | BRD4 (0.42) | BRD4 | |
| SCHEMBL9282455 | 0.68 | BRD4 (0.83) | BRD4 | |
| SCHEMBL15925864 | 0.68 | BRD4 (0.83) | BRD4 | |
| SCHEMBL9974032 | 0.68 | BRD4 (0.70) | BRD4 | |
| SCHEMBL9974034 | 0.68 | BRD4 (0.78) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9522920-B2 | Bromodomain inhibitors and uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2016-12-20 | — | — | US | disclosed |
| US-20140371206-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2014-12-18 | — | — | US | disclosed |
| US-8796261-B2 | Bromodomain inhibitors and uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-20120157428-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157428-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | BRD4, BRPF3, BRDT | BRD4 1/4885 |
| US-20140371206-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | BRD4, BRPF3, BRDT | BRD4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.